


BEST AVAILABLE COPY

A.



B.



Polypeptide 1

Polypeptide 2

C.




Figure 1

FIGURE 1D

1) Amino acid sequence of Polypeptide 1. EAEAEFM-h679VH-GGGGS-hMN-14VK-LEGGGS-hMN-14VH-VD6His.

**EAEAEFMEVQ LVEGGDLVK PGGSLKLSA ASGFTFSIYT MSWLRQTPGK**  
CDR1h679VH

**GLEWVATLSG DGDDIYYPDS VKGRFTISRD NAKNSLYLQM NSLRAEDTAL**  
CDR2h679VH

**YYCARVRLGD WDFDVWGQGT TVSVSSGGGG SDIQLTQSPS SLSASVGDRV**  
CDR3h679VH linker

**TITCKASQDV GTSVAWYQQK PGKAPKLLIY WTSTRHTGVP SRFGSGSGT**  
CDR1hMN14VK CDR2hMN14VK

**DFTFTISSLQ PEDIATYYCQ QYSLYRSFGQ GTKVEIKRLE GGGSEVQLVE**  
CDR3hMN14VK linker

**SGGGVVQPGR SLRLSCSASG FDFTTYWMSW VRQAPGKGLE WIGEIHPDSS**  
CDR1hMN14VH CDR2hMN14VH

**TINYAPSLKD RFTISRDNAK NTLFLQMDSL RPEDTGKVFC ASLYFGFPWF**  
CDR2hMN14VH CDR3hMN14VH

**AYWGQGTPVTVSVDHHHHHH**  
CDR3hMN14VH 6His

Nucleic acid sequence (cDNA) of BS14HP polypeptide 1

GAGGCTGAAG CTGAATTCACT GGAAGTGCAG CTGGTGGAGT CAGGGGGAGA  
CTTAGTGAAG CCTGGAGGGT CCCTGAAACT CTCCCTGTGCA GCCTCTGGAT  
TCACCTTCAG TATTTACACC ATGTCTTGGC TTCCGCCAGAC TCCGGGAAAG  
GGGCTGGAGT GGGTCGCAAC CCTGAGTGGT GATGGTGATG ACATCTACTA  
TCCAGACAGT GTGAAGGGTC GATTCAACCAT CTCCAGAGAC AATGCCAAGA  
ACAGCCTATA TCTGCAGATG AACAGTCTAA GGGCTGAGGA CACGGCCTTG  
TATTACTGTG CAAGGGTGC GACTTGGGAC TGGGACTTCG ATGTCTGGG  
CCAAGGGACC ACGGTCTCCG TCTCCTCAGG AGGTGGCGGA TCCGACATCC  
AGCTGACCCA GAGCCCAAGC AGCCTGAGCG CCAGCGTGGG TGACAGAGTG  
ACCATCACCT GTAAGGCCAG TCAGGATGTG GGTACTTCTG TAGCTTGGTA  
CCAGCAGAAG CCAGGTAAGG CTCCAAAGCT GCTGATCTAC TGGACATCCA  
CCCGGCACAC TGGTGTGCCA AGCAGATTCA GCGGTAGCGG TAGCGGTACC  
GACTTCACCT TCACCACATCAG CAGCCTCCAG CCAGAGGACA TCGCCACCTA  
CTACTGCCAG CAATATAGCC TCTATCGGTC GTTCGGCCAA GGGACCAAGG  
TGGAAATCAA ACGTCTCGAG GGCAGGAGGTA GCGAGGTCCA ACTGGTGGAG  
AGCGGGTGGAG GTGTTGTGCA ACCTGGCCGG TCCCTGCGCC TGTCTGCTC  
CGCATTCTGGC TTCGATTTCAC CCACATATTG GATGAGTTGG GTGAGACAGG  
CACCTGGAAA AGGTCTTGAG TGGATTGGAG AAATTCACTCC AGATAGCAGT

Edmund A. ROSSI et al.  
"Polyvalent Protein Complex"  
Attorney Docket No. 41133-0006US1

ACGATTAAC T ATGCCCGTC TCTAAAGGAT AGATTTACAA TATCGCGAGA  
CAACGCCAAG AACACATTGT TCCTGCAAAT GGACAGCCTG AGACCCGAAG  
ACACCGGGGT CTATTTTGT GCAAGCCTT ACTTCGGCTT CCCCTGGTTT  
GCTTATTGGG GCCAAGGGAC CCCGGTCACC GTCTCCGTCG ACCATCATCA  
TCATCATCAT

FIGURE 1E

3) Amino acid sequence of polypeptide 2. EAEAEF-hMN-14VK-GGGQFM-hMN-14VH-GGGGS-h679VK-LD6His.

EAEAEFDIQL TQSPSSLSAS VGDRVITITCK ASQDVGTSA WYQQKPGKAP  
CDR1hMN14VK

KLLIYWTSTR HTGVPSRFSG SGSGTDFTFT ISSLQPEDIA TYYCQQYSLY  
CDR2hMN14VK CDR3hMN14VK

RSFGQGTKVE IKRGGGQFME VQLVESGGGV VQPGRSLRLS CSASGFDFT  
CDR3hMN14VK linker CDR1hMN14VH

YWMSWVRQAP GKGLEWIGEI HPDSSTINYA PSLKDRFTIS RDNAKNTLFL  
CDR1hMN14VH CDR2hMN14VH

QMDSL RPEDT GVYFCASLYF GFPWFAYWGQ GTPVTVSGGG GSDIVMTQSP

CDR3hMN14VH linker

SSLA VSPGER VTLTCKSSQS LFNSRTRKNY LGWYQQKPGQ SPKLLIYWAST  
CDR1h679VK CDR2h679VK

RESGPDRFS GSGSGTDFTL TINSLQAEDV AVYYCTQVYY LCTFGAGTKLE  
CDR2h679VK CDR3h679VK

LKR LDHHHHH H  
6His

Nucleic acid sequence (cDNA) of BS14HP polypeptide 2

GAGGCTGAAG CTGAATTCTGA CATCCAGCTG ACCCAGAGGCC CAAGCAGCCT  
GAGCGCCAGC GTGGGTGACA GAGTGACCAT CACCTGTAAG GCCAGTCAGG  
ATGTGGGTAC TTCTGTAGCT TGGTACCCAGC AGAAGCCAGG TAAGGCTCCA  
AAGCTGCTGA TCTACTGGAC ATCCACCCGG CACACTGGTG TGCCAAGCAG  
ATTCA CGCGGT AGCGGTAGCG GTACCGACTT CACCTTCACC ATCAGCAGCC  
TCCAGCCAGA GGACATCGCC ACCTACTACT GCCAGCAATA TAGCCTCTAT  
CGGTCGTTCG GCCAAGGGAC CAAGGTGGAA ATCAAACGTG GAGGTGGCCA  
ATTCA TGAGAGCGG TGGAGAGCGG TGGAGGTGTT GTGCAACCTG  
GCCGGTCCCT GCGCCTGTCC TGCTCCGCAT CTGGCTTCGA TTTCACCA  
TATTGGATGA GTTGGGTGAG ACAGGCACCT GGAAAAGGTC TTGAGTGGAT  
TGGAGAAATT CATCCAGATA GCAGTACGAT TAACTATGCG CCGTCTCTAA  
AGGATAGATT TACAATATCG CGAGACAAACG CCAAGAACAC ATTGTTCTG  
CAAATGGACA GCCTGAGACC CGAAGACACC GGGGTCTATT TTTGTGCAAG  
CCTTACTTC GGCTTCCCT GGTTTGCTTA TTGGGGCCAA GGGACCCGG  
TCACCGTCTC CGGAGGCAGT GGATCCGACA TTGTGATGAC ACAATCTCCA

Edmund A. ROSSI et al.  
"Polyvalent Protein Complex"  
Attorney Docket No. 41133-0006US1

TCCTCCCTGG CTGTGTCACC CGGGGAGAGG GTCACTCTGA CCTGCAAATC  
CAGTCAGAGT CTGTTCAACA GTAGAACCCG AAAGAACTAC TTGGGTTGGT  
ACCAGCAGAA ACCAGGGCAG TCTCCTAAC ACCTGATCTA CTGGGCATCT  
ACTCGGAAT CTGGGTCCC TGATCGCTTC TCAGGCAGTG GATCCGGAAC  
AGATTTCACT CTCACCACATCA ACAGTCTGCA GGCTGAAGAC GTGGCAGTTT  
ATTACTGCAC TCAAGTTAT TATCTGTGCA CGTCGGTGC TGGGACCAAG  
CTGGAGCTGA AACGGCTCGA CCATCATCAT CATCATCAT

BEST AVAILABLE COPY




Figure 2

## BIACore analysis of BS14HP




Figure 3

Edmund A. ROSSI et al.  
"Polyvalent Protein Complex"  
Attorney Docket No. 41133-0006US1

SDS-PAGE Analysis of BS14HP  
B/N 111802

BEST AVAILABLE COPY




Figure 4

Edmund A. ROSSI et al.  
"Polyvalent Protein Complex"  
Attorney Docket No. 41133-0006US1

#### Size exclusion HPLC analysis




Figure 5

BEST AVAILABLE COPY

### Competitive ELISA assay for CEA binding




Figure 6




Figure 6B SE-HPLC Analysis of BS14HP immunoreactivity with CEA

BEST AVAILABLE COPY

Tumor retention and blood clearance  
of  $^{125}\text{I}$ -BS14HP





Figure 7

BEST AVAILABLE COPY

- A. Biodistribution of  $^{111}\text{In}$ -IMP241 in mice pretargeted with BS14HP, BS1.5H or hMN14 x 679.Fab' x Fab'



- B. Tumor/non-tumor ratios of  $^{111}\text{In}$ -IMP241 in mice pretargeted with BS14HP, BS1.5H or hMN-14 x 679.Fab' x Fab'

	BS14HP	hMN-14 x 679	BS1.5H
Liver	36.19 ( $\pm$ 18.8)	22.20 ( $\pm$ 6.3)	120.00 ( $\pm$ 36.0)
Spleen	57.39 ( $\pm$ 46.0)	27.80 ( $\pm$ 5.9)	181.00 ( $\pm$ 58.0)
Kidney	6.70 ( $\pm$ 0.7)	2.50 ( $\pm$ 0.5)	2.98 (1.1 $\pm$ )
Lungs	29.94 ( $\pm$ 15.6)	14.10 ( $\pm$ 2.8)	48.60 ( $\pm$ 19.3)
Blood	20.32 ( $\pm$ 34.7)	8.10 ( $\pm$ 2.1)	284.00 ( $\pm$ 50.6)
Stomach	123.12 ( $\pm$ 242.0)	103.00 ( $\pm$ 15.2)	530.00 ( $\pm$ 291.7)
Sm. Intestine	78.95 ( $\pm$ 55.0)	53.40 ( $\pm$ 14.4)	235.00 ( $\pm$ 138.7)
Lg. Intestine	80.94 ( $\pm$ 26.7)	37.40 ( $\pm$ 9.2)	61.20 ( $\pm$ 33.2)

Figure 8




Figure 8C

IMP 281





Figure 9A

Edmund A. ROSSI et al.  
"Polyvalent Protein Complex"  
Attorney Docket No. 41133-0006US1

IMP 284



**Figure 9B**




Figure 9C

Edmund A. ROSSI et al.  
"Polyvalent Protein Complex"  
Attorney Docket No. 41133-0006US1

**Functional features of the SV3 shuttle vector.**

[HindIII—Xhol—XbaI—Leader peptide—NcoI—SalI—6His—Stop—Stop—BglII—EagI—EcoRI]

**Figure 10 A**

**Features of the ORF/Polyptide 1, and ORF/Polyptide 2**

**ORF1/Polyptide 1**

Ldr Pep—h679V<sub>H</sub>—GGGGS—hMN-14V<sub>K</sub>—LEGGGS—hMN-14V<sub>H</sub>—HHHHHH

**ORF2/Polyptide 2**

Ldr Pep—hMN-14V<sub>K</sub>—GGGQFM—hMN-14V<sub>H</sub>—GGGGS—h679V<sub>K</sub>—HHHHHH

**Figure 10B**

BEST AVAILABLE COPY






Figure 11. Schematic representation of hBS14-pDHL2 expression vector.



**Figure 12.** MTX amplification of hBS14 SP2/0 clone 1H6

BEST AVAILABLE COPY

hBS14 102003  
YB2/0



hBS14 100103  
SP2/0




Figure 13. SE-HPLC analysis of purified hBS14

BEST AVAILABLE COPY






Figure 14. SDS-PAGE analysis of purified hBS14

Edmund A. ROSSI et al.  
"Polyvalent Protein Complex"  
Attorney Docket No. 41133-0006US1


BEST AVAILABLE COPY



**Figure 15.** IEF analysis of purified hBS14



**Figure 16.** BIACore analysis of hBS14



**Figure 17.** BIAcore analysis of HSG binding of hBS14 produced in either SP2/0 or YB2/0 cells

Figure 18

IMP 291 Ac-Lys(HSG-iAsp-)-Cys-NH<sub>2</sub> MH<sup>+</sup> 656




Figure 19

IMP 245 DOTA-Phe-Lys(HSG)-D-Tyr-Lys(HSG)-Lys(Tscg-Cys-)-NH<sub>2</sub> MH<sup>+</sup> 1832





Figure 20

**Pre-Targeting of  $^{99m}\text{Tc}$ -IMP-245 by hBS14 (4 hr)  
in GW-39 Tumor-Bearing Mice**



**Pre-Targeting of  $^{99m}\text{Tc}$ -IMP-245 by hBS14 (24 hr)  
in GW-39 Tumor-Bearing Mice**






Figure 21



BEST AVAILABLE COPY

Figure 22

Percent ID/g and Tumor Non-Tumor Ratios of $^{99m}\text{Tc}$ -IMP-245 at 1 hr Post-Injection.						
Tissue	4 hrs hBS14		24 hrs hBS14		48 hr hBS14	
	%ID/g ± (SD)	T:NT Ratio ± (SD)	%ID/g ± (SD)	Clearance	T:NT Ratio ± (SD)	%ID/g ± (SD)
GW-39	2.9 ± 0.5		22.2 ± 6.1		22.0 ± 2.5	
Liver	8.3 ± 0.6	0.4 ± 0.07	1.5 ± 0.8	17.5 ± 6.5	1.1 ± 0.2	19.7 ± 3.6
Spleen	7.5 ± 1.9	0.4 ± 0.08	0.9 ± 0.3	27.7 ± 9.4	0.5 ± 0.1	41.3 ± 9.7
Kidney	15.4 ± 1.1	0.2 ± 0.03	5.3 ± 0.8	4.4 ± 0.7	7.9 ± 0.8	2.7 ± 0.5
Lungs	10.7 ± 3.1	0.3 ± 0.10	1.7 ± 0.7	14.1 ± 4.8	1.0 ± 0.4	23.0 ± 6.8
Blood	36.9 ± 16.4	0.1 ± 0.01	7.7 ± 8.7	5.7 ± 3.4	1.6 ± 0.3	13.6 ± 2.3
Stomach	1.3 ± 0.4	2.4 ± 0.67	4.0 ± 7.6	29.4 ± 18.8	3.5 ± 0.9	6.4 ± 2.0
Small Int.	3.7 ± 0.3	0.8 ± 0.07	3.9 ± 5.3	11.8 ± 6.4	2.4 ± 0.5	8.8 ± 1.5
Large Int.	2.2 ± 1.7	1.8 ± 0.98	0.4 ± 0.2	69.4 ± 31.2	0.4 ± 0.1	56.0 ± 11.5
Muscle	1.2 ± 0.2	2.4 ± 0.32	4.8 ± 6.4	19.1 ± 26.3	4.1 ± 5.0	18.4 ± 25.6
Tumor Weight (grams)	0.309 ± 0.139		0.309 ± 0.136		0.972 ± 0.640	

Figure 23

BEST AVAILABLE COPY

